CN1209098C - 提供药物长效治疗的方法和装置 - Google Patents

提供药物长效治疗的方法和装置 Download PDF

Info

Publication number
CN1209098C
CN1209098C CNB998069701A CN99806970A CN1209098C CN 1209098 C CN1209098 C CN 1209098C CN B998069701 A CNB998069701 A CN B998069701A CN 99806970 A CN99806970 A CN 99806970A CN 1209098 C CN1209098 C CN 1209098C
Authority
CN
China
Prior art keywords
drug
dosage form
layer
release
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998069701A
Other languages
English (en)
Chinese (zh)
Other versions
CN1352549A (zh
Inventor
A·D·艾尔
C·A·克里斯朵夫
D·R·金塔
S·K·古普塔
L·G·哈梅尔
Z·哈特姆哈内
A·C·兰
S·R·萨克斯
P·沙瓦南德
R·G·魏尔斯
J·D·赖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/253,317 external-priority patent/US6919373B1/en
Application filed by Alza Corp filed Critical Alza Corp
Publication of CN1352549A publication Critical patent/CN1352549A/zh
Application granted granted Critical
Publication of CN1209098C publication Critical patent/CN1209098C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/88—Investigating the presence of flaws or contamination
    • G01N21/95—Investigating the presence of flaws or contamination characterised by the material or shape of the object to be examined
    • G01N21/9508—Capsules; Tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB998069701A 1998-06-03 1999-05-27 提供药物长效治疗的方法和装置 Expired - Lifetime CN1209098C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8778798P 1998-06-03 1998-06-03
US60/087,787 1998-06-03
US09/253,317 US6919373B1 (en) 1996-11-12 1999-02-19 Methods and devices for providing prolonged drug therapy
US09/253,317 1999-02-19

Publications (2)

Publication Number Publication Date
CN1352549A CN1352549A (zh) 2002-06-05
CN1209098C true CN1209098C (zh) 2005-07-06

Family

ID=26777397

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998069701A Expired - Lifetime CN1209098C (zh) 1998-06-03 1999-05-27 提供药物长效治疗的方法和装置

Country Status (16)

Country Link
EP (2) EP1449524A1 (https=)
JP (1) JP2002516848A (https=)
KR (1) KR20080083074A (https=)
CN (1) CN1209098C (https=)
AT (1) ATE277594T1 (https=)
AU (1) AU4319799A (https=)
CA (1) CA2333688A1 (https=)
DE (1) DE69920689T2 (https=)
DK (1) DK1083879T3 (https=)
ES (1) ES2229783T3 (https=)
HK (1) HK1046638B (https=)
IL (1) IL140020A0 (https=)
NO (1) NO330235B1 (https=)
NZ (1) NZ508567A (https=)
PT (1) PT1083879E (https=)
WO (1) WO1999062496A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827234B1 (en) 2017-02-03 2017-11-28 Osmotica Kereskedelmi és Szolgáltató KFT Dose-dumping resistant controlled release dosage form

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
CN1404388A (zh) * 2000-01-20 2003-03-19 德尔西斯药品公司 多级药物剂型
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
CA2461616A1 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR100699516B1 (ko) * 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
EP1542662A1 (en) * 2002-09-28 2005-06-22 McNEIL-PPC, INC. Immediate release dosage form comprising shell having openings therein
GR1004330B (el) * 2002-10-14 2003-09-05 Lavipharm A.E. Φαρμακοτεχνικη μορφη για τη χορηγηση οργανικων νιτρικων ενωσεων
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1592410B1 (en) * 2003-02-11 2008-07-23 Alza Corporation Methods and dosage forms with modified layer geometry
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
ATE526988T1 (de) * 2003-10-08 2011-10-15 Mallinckrodt Llc Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
ES2385832T3 (es) * 2004-05-21 2012-08-01 Accu-Break Technologies, Inc. Comprimidos farmacéuticos que presentan un segmento relativamente inactivo
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2009023006A2 (en) * 2006-05-08 2009-02-19 Mcneil-Ppc, Inc. Modified release dosage form
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
AU2010328353B2 (en) 2009-12-07 2015-07-16 Mcneil-Ppc, Inc. Partial dip coating of dosage forms for modified release
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2020154580A1 (en) * 2019-01-25 2020-07-30 Ironshore Pharmaceuticals & Development, Inc. Methylphenidate compositions for treatment of attention deficit hyperactivity disorder
CA3130379A1 (en) 2019-03-05 2020-09-10 Kashiv Biosciences, Llc Delayed release methylphenidate compositions
CN114681422B (zh) * 2020-12-30 2023-09-05 深圳翰宇药业股份有限公司 一种硝苯地平控释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
ES2194210T3 (es) * 1996-08-16 2003-11-16 Alza Corp Forma de dosificacion para suministrar una dosis ascendente de farmaco.
ES2262174T3 (es) * 1996-09-30 2006-11-16 Alza Corporation Forma de dosificacion y procedimiento de administracion de medicamentos.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827234B1 (en) 2017-02-03 2017-11-28 Osmotica Kereskedelmi és Szolgáltató KFT Dose-dumping resistant controlled release dosage form
US9855258B1 (en) 2017-02-03 2018-01-02 Osmotica Kereskedelmi és Szolgáltató KFT Dose-dumping resistant controlled release dosage form
US10265308B2 (en) 2017-02-03 2019-04-23 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US10695336B2 (en) 2017-02-03 2020-06-30 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form

Also Published As

Publication number Publication date
CA2333688A1 (en) 1999-12-09
NO330235B1 (no) 2011-03-07
ATE277594T1 (de) 2004-10-15
NZ508567A (en) 2004-02-27
HK1046638A1 (en) 2003-01-24
HK1046638B (zh) 2006-02-24
EP1083879A1 (en) 2001-03-21
ES2229783T3 (es) 2005-04-16
IL140020A0 (en) 2002-02-10
NO20006007L (no) 2001-02-05
KR20080083074A (ko) 2008-09-12
HK1035492A1 (en) 2001-11-30
NO20006007D0 (no) 2000-11-28
PT1083879E (pt) 2005-01-31
JP2002516848A (ja) 2002-06-11
DE69920689T2 (de) 2005-02-24
EP1449524A1 (en) 2004-08-25
WO1999062496A1 (en) 1999-12-09
DE69920689D1 (de) 2004-11-04
EP1083879B1 (en) 2004-09-29
DK1083879T3 (da) 2005-01-31
CN1352549A (zh) 2002-06-05
AU4319799A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
CN1209098C (zh) 提供药物长效治疗的方法和装置
US9029416B2 (en) Methods and devices for providing prolonged drug therapy
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
CN1819821A (zh) 盐酸安非他酮的改良释放片剂
US20150250746A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2002516848A5 (https=)
US20130245004A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
CN1993112A (zh) 用于具有高度pH依赖性溶解度的活性成分的控释的药物多层片剂
CN1905856A (zh) 用于增加受控递送的药物组合物的溶解度的方法和剂型
JP2015028095A (ja) 長時間の薬物療法を与える方法および装置
SG178325A1 (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
AU2013290100A1 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN1520285A (zh) 包含西替利嗪和伪麻黄碱的片剂
AU2012345659B2 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
TW200520748A (en) Modafinil modified release pharmaceutical compositions
CN1832729A (zh) 长时间释放弱碱的组合物
JP2008542394A (ja) 少なくとも１つの形態のベンラファキシンの調節放出性組成物
KR100890537B1 (ko) 연장된 약물 치료를 제공하기 위한 방법 및 장치
FR2887455A1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
AU2012232984B2 (en) Methods and devices for providing prolonged drug therapy
CN1942175A (zh) 24小时有效的曲马朵缓释制剂
HK1068799A (en) Methods and devices for providing prolonged drug therapy
AU2004201230A1 (en) Methods and devices for providing prolonged drug therapy

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20050706

CX01 Expiry of patent term